Haemonetics (HAE) Stock Analysis & AI Equity Report
Haemonetics (HAE) overview
Haemonetics (HAE) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 1,334m and operating profit of USD 157m; the year-end share price was 54.04 USD and market capitalisation was USD 2,445m. Haemonetics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Haemonetics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Haemonetics
Haemonetics is a medical technology company offering hospital technologies, plasma collection systems, and products for blood centers. Its products include automated plasma collection devices, donor management software, blood collection and processing devices, and hospital technologies for vascular closure, hemostasis, cell salvage and transfusion management. Customers include plasma collection centers, blood centers and hospitals.
Generate the Haemonetics report
Haemonetics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Haemonetics and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Haemonetics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.